Teva Pharmaceutical Industries Limited (TEVA) Revenue by Segment

Teva Pharmaceutical Industries revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), Teva Pharmaceutical Industries's largest business segment was United States, with $1.70 billion or 41% of revenue, down 4.7% from a year earlier. Next: Europe (30%), Other Activities (15%) and International Markets (13%).

By product or service, Product brought in 87%, Distribution Service brought in 10% and Other brought in 2% of revenue in Q2 fiscal 2026.

By region, UNITED STATES brought in 57% and Europe brought in 43% of revenue in Q2 fiscal 2026.

The fastest-growing business segment from a year earlier was International Markets (+11.1%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Teva Pharmaceutical Industries Limited

TEVAHealthcare Israel

Israel

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

North AmericaEuropeUnited StatesInternational MarketsOther Activities

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before
United States	USD 1.70B	41.1%	-4.7%
Europe	USD 1.26B	30.5%	-2.7%
Other Activities	USD 627.00M	15.1%	+5.0%
International Markets	USD 550.00M	13.3%	+11.1%

Sum of items USD 4.14B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
North America	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.0B	1.8B	1.9B	1.7B	2.0B	1.9B	1.9B	2.0B	2.3B	2.0B	2.0B	2.1B	2.4B	2.1B	2.1B	2.0B	2.2B	2.3B	2.3B	2.5B	–	3.0B
Europe	1.3B	1.3B	1.3B	1.2B	1.3B	1.2B	1.4B	1.3B	1.2B	1.3B	1.3B	1.1B	1.2B	1.2B	1.1B	1.1B	1.2B	1.2B	1.3B	1.2B	1.2B	1.2B	1.2B	1.1B	1.0B	1.4B	1.2B	1.2B	1.2B	1.3B	1.2B	1.2B	1.3B	1.4B	–	1.4B
United States	1.7B	1.5B	2.6B	2.5B	1.8B	1.5B	2.0B	2.2B	2.1B	1.7B	2.3B	1.9B	1.9B	1.7B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
International Markets	550.0M	524.0M	528.0M	557.0M	495.0M	582.0M	660.0M	613.0M	593.0M	597.0M	601.0M	591.0M	578.0M	581.0M	481.0M	475.0M	454.0M	492.0M	527.0M	530.0M	485.0M	490.0M	572.0M	529.0M	488.0M	565.0M	578.0M	565.0M	582.0M	521.0M	740.0M	726.0M	789.0M	750.0M	–	882.0M
Other Activities	627.0M	584.0M	226.0M	205.0M	597.0M	579.0M	241.0M	229.0M	249.0M	225.0M	245.0M	217.0M	245.0M	219.0M	272.0M	241.0M	257.0M	275.0M	302.0M	262.0M	298.0M	289.0M	344.0M	316.0M	335.0M	307.0M	331.0M	314.0M	342.0M	317.0M	377.0M	326.0M	321.0M	342.0M	–	312.0M

Teva Pharmaceutical Industries revenue by business segment, last 4 quarters

Business segment	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
United States	$1.7B	$1.5B	$2.5B	$1.8B	41%
Europe	$1.3B	$1.3B	$1.2B	$1.3B	30%
Other Activities	$627.0M	$584.0M	$205.0M	$597.0M	15%
International Markets	$550.0M	$524.0M	$557.0M	$495.0M	13%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Teva Pharmaceutical Industries revenue by product or service, last 4 quarters

Product or service	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Product	$3.6B	$3.4B	$3.9B	$3.6B	87%
Distribution Service	$433.0M	$396.0M	$406.0M	$377.0M	10%
Other	$70.0M	$157.0M	$121.0M	$117.0M	2%
License	$37.0M	$39.0M	$46.0M	$46.0M	1%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Teva Pharmaceutical Industries revenue by region, last 4 quarters

Region	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
UNITED STATES	$1.7B	$1.5B	$2.5B	$1.8B	57%
Europe	$1.3B	$1.3B	$1.2B	$1.3B	43%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

What are Teva Pharmaceutical Industries's business segments?

United States, Europe, Other Activities and International Markets (as reported for Q2 fiscal 2026).

Which business segment makes the most money for Teva Pharmaceutical Industries?

United States: $1.70 billion, or 41% of revenue, in Q2 fiscal 2026.

What are Teva Pharmaceutical Industries's main products and services?

By revenue in Q2 fiscal 2026: Product (87%), Distribution Service (10%), Other (2%) and License (1%).

Where does Teva Pharmaceutical Industries make its money?

By region in Q2 fiscal 2026: UNITED STATES (57%) and Europe (43%).

MoreTeva Pharmaceutical Industries stock overview Teva Pharmaceutical Industries financials Teva Pharmaceutical Industries executive team Teva Pharmaceutical Industries shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

North AmericaEuropeUnited StatesInternational MarketsOther Activities

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before
United States	USD 1.70B	41.1%	-4.7%
Europe	USD 1.26B	30.5%	-2.7%
Other Activities	USD 627.00M	15.1%	+5.0%
International Markets	USD 550.00M	13.3%	+11.1%

Sum of items USD 4.14B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
North America	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.0B	1.8B	1.9B	1.7B	2.0B	1.9B	1.9B	2.0B	2.3B	2.0B	2.0B	2.1B	2.4B	2.1B	2.1B	2.0B	2.2B	2.3B	2.3B	2.5B	–	3.0B
Europe	1.3B	1.3B	1.3B	1.2B	1.3B	1.2B	1.4B	1.3B	1.2B	1.3B	1.3B	1.1B	1.2B	1.2B	1.1B	1.1B	1.2B	1.2B	1.3B	1.2B	1.2B	1.2B	1.2B	1.1B	1.0B	1.4B	1.2B	1.2B	1.2B	1.3B	1.2B	1.2B	1.3B	1.4B	–	1.4B
United States	1.7B	1.5B	2.6B	2.5B	1.8B	1.5B	2.0B	2.2B	2.1B	1.7B	2.3B	1.9B	1.9B	1.7B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
International Markets	550.0M	524.0M	528.0M	557.0M	495.0M	582.0M	660.0M	613.0M	593.0M	597.0M	601.0M	591.0M	578.0M	581.0M	481.0M	475.0M	454.0M	492.0M	527.0M	530.0M	485.0M	490.0M	572.0M	529.0M	488.0M	565.0M	578.0M	565.0M	582.0M	521.0M	740.0M	726.0M	789.0M	750.0M	–	882.0M
Other Activities	627.0M	584.0M	226.0M	205.0M	597.0M	579.0M	241.0M	229.0M	249.0M	225.0M	245.0M	217.0M	245.0M	219.0M	272.0M	241.0M	257.0M	275.0M	302.0M	262.0M	298.0M	289.0M	344.0M	316.0M	335.0M	307.0M	331.0M	314.0M	342.0M	317.0M	377.0M	326.0M	321.0M	342.0M	–	312.0M